Jerusalem, Israel, November 15, 2014 – Vidac Pharma, a drug discovery and development company, today announced the appointment of Chaim M. Brickman, M.D. as its vice president of clinical affairs. Chaim will oversee all clinical development activities for the company, as Vidac rapidly advances its product candidates in human clinical trials for a range of dermatology and oncology indications. Dr. Brickman brings to Vidac more than 35 years of experience in medical practice, laboratory and clinical research, drug development, clinical operations, safety monitoring and regulatory experience. He will report directly to Vidac’s president and CEO, Dr. Oren M. Becker, and will serve as a member of the company’s executive management team.
“We are excited to welcome Dr. Chaim Brickman to Vidac’s senior clinical development position,” said Dr. Oren M. Becker. “Chaim is an exceptional individual and his proven leadership will be critical to our success as we work to advance our proprietary pipeline through clinical development.”
Chaim received his medical degree from the Albert Einstein Medical Center, internal medicine certification at Wayne State University Medical Center, and fellowship training at the National Institute of Allergy and Infectious Diseases (NIAID, NIH). After holding teaching, research, and leadership roles at the NIH, Uniformed Services Medical Center (Maryland), Wayne State University Medical Center, Sinai Hospital of Detroit’s Research Institute, and Wolfson Medical Center (Israel), Chaim held senior positions at Inotek Pharmaceuticals Corporation (USA) and Teva Pharmaceuticals (Israel) where he helped manage Phase I-III clinical trials in the US, Israel, Western Europe, Australia, India, and Eastern Europe. In addition, Dr. Brickman has chaired an Institutional Review Board in the United States and served as medical monitor for numerous international pharmaceutical companies and Contract Research Organizations.
“Vidac’s therapeutics have the potential of addressing significant unmet medical needs in the fields of dermatology and oncology,” said Dr. Brickman. “I look forward to working with the Vidac team to advance our lead compound, VDA-1102, and other new development programs.”
About Vidac Pharma
Vidac Pharma is an innovative biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncology and dermatology ailments. Vidac’s breakthrough technology targets the VDAC/HK2 system that is unique to malignant cells. Modulating this target leads to selective apoptosis of cancer cells without affecting the surrounding healthy tissue, thus holds the promise of delivering novel drugs that are both efficacious and well tolerated by patients. Vidac expects to start clinical studies with VDA-1102 ointment in subjects with actinic keratosis in early 2016. For more information on Vidac Pharma, please visit www.vidacpharma.com.